4.4 Article

Male Pattern Baldness in Relation to Prostate Cancer Risks: An Analysis in the VITamins and Lifestyle (VITAL) Cohort Study

期刊

PROSTATE
卷 75, 期 4, 页码 415-423

出版社

WILEY
DOI: 10.1002/pros.22927

关键词

male pattern baldness; prostate cancer; androgen; cohort study

资金

  1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health

向作者/读者索取更多资源

BACKGROUNDMale pattern baldness and prostate cancer may share common pathophysiological mechanisms in terms of advancing age, heritability, and endogenous hormones. Results from previous epidemiologic studies are inconsistent. Therefore, we investigated the association of prostate cancer risks with male pattern baldness at age 30 years, age 45 years, and baseline (median age=60.5 years) in the VITamins And Lifestyle (VITAL) cohort study. METHODSWe included 32,583 men who were aged 50-76 years and without prior cancer diagnosis (excluding non-melanoma skin cancer) at the start of follow-up. First primary incident prostate cancers were ascertained via linkage to the western Washington Surveillance, Epidemiology, and End Results (SEER) program. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were estimated using Cox proportional hazards regressions with adjustment for potential confounders. RESULTSDuring follow-up (median=9 years), 2,306 incident prostate cancers were diagnosed. Male pattern baldness at age 30 years, age 45 years, and baseline were not statistically significantly associated with overall or subtypes of prostate cancer. CONCLUSIONThis study did not provide support for the hypothesis that male pattern baldness may be a marker for subsequent prostate cancer. Previous evidence indicates that a distinct class of frontal with vertex balding may be associated with increased risk of aggressive prostate cancer, but all such balding classes were captured as a single exposure category by the VITAL cohort questionnaire. Prostate 75:415-423, 2015. (c) 2014 Wiley Periodicals, Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Urinary Thromboxane B2 and Lethal Prostate Cancer in African American Men

Maeve Kiely, Ginger L. Milne, Tsion Z. Minas, Tiffany H. Dorsey, Wei Tang, Cheryl J. Smith, Francine Baker, Christopher A. Loffredo, Clayton Yates, Michael B. Cook, Stefan Ambs

Summary: In this study, we found that high levels of TXB2 were associated with prostate cancer and poor outcomes in African American men, indicating a potential role of upregulated TXA2 synthesis in promoting disease progression and metastasis. Our findings suggest a potential benefit of aspirin in preventing lethal prostate cancer through inhibition of TXA2 synthesis, especially in high-risk populations like African American men.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)

Article Urology & Nephrology

A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry

Burcu F. Darst, Raymond Hughley, Aaron Pfennig, Ujani Hazra, Caoqi Fan, Peggy Wan, Xin Sheng, Lucy Xia, Caroline Andrews, Fei Chen, Sonja Berndt, Zsofia Kote-Jarai, Koveela Govindasami, Jeannette T. Bensen, Sue A. Ingles, Benjamin A. Rybicki, Barbara Nemesure, Esther M. John, Jay H. Fowke, Chad D. Huff, Sara S. Strom, William B. Isaacs, Jong Y. Park, Wei Zheng, Elaine A. Ostrander, Patrick C. Walsh, John Carpten, Thomas A. Sellers, Kosj Yamoah, Adam B. Murphy, Maureen Sanderson, Dana C. Crawford, Susan M. Gapstur, William S. Bush, Melinda C. Aldrich, Olivier Cussenot, Gyorgy Petrovics, Jennifer Cullen, Christine Neslund-Dudas, Rick A. Kittles, Jianfeng Xu, Mariana C. Stern, Anand P. Chokkalingam, Luc Multigner, Marie-Elise Parent, Florence Menegaux, Geraldine Cancel-Tassin, Adam S. Kibel, Eric A. Klein, Phyllis J. Goodman, Janet L. Stanford, Bettina F. Drake, Jennifer J. Hu, Peter E. Clark, Pascal Blanchet, Graham Casey, Anselm J. M. Hennis, Alexander Lubwama, Ian M. Thompson, Robin J. Leach, Susan M. Gundell, Loreall Pooler, James L. Mohler, Elizabeth T. H. Fontham, Gary J. Smith, Jack A. Taylor, Laurent Brureau, William J. Blot, Richard Biritwum, Evelyn Tay, Ann Truelove, Shelley Niwa, Yao Tettey, Rohit Varma, Roberta McKean-Cowdin, Mina Torres, Mohamed Jalloh, Serigne Magueye Gueye, Lamine Niang, Olufemi Ogunbiyi, Michael Oladimeji Idowu, Olufemi Popoola, Akindele O. Adebiyi, Oseremen Aisuodionoe-Shadrach, Maxwell Nwegbu, Ben Adusei, Sunny Mante, Afua Darkwa-Abrahams, Edward D. Yeboah, James E. Mensah, Andrew Anthony Adjei, Halimatou Diop, Michael B. Cook, Stephen J. Chanock, Stephen Watya, Rosalind A. Eeles, Charleston W. K. Chiang, Joseph Lachance, Timothy R. Rebbeck, David Conti, Christopher A. Haiman

Summary: A specific germline deletion variant in HOXB13 (X285K) was found to be associated with an increased risk of prostate cancer in men of West African ancestry. This variant was more strongly associated with aggressive and advanced disease. Understanding who carries this variant can inform prostate cancer screening in men of West African ancestry.

EUROPEAN UROLOGY (2022)

Article Oncology

Testosterone therapy and cancer risks among men in the SEER-Medicare linked database

Ebonee N. Butler, Cindy Ke Zhou, Michael Curry, Una McMenamin, Christopher Cardwell, Marie C. Bradley, Barry Graubard, Michael B. Cook

Summary: This study found an inverse association between testosterone therapy (TT) and the risk of distant-stage prostate and colorectal cancers, but a positive association with distant-stage melanoma. These findings suggest a potential role for TT in the etiology of these cancers or the presence of residual confounding.

BRITISH JOURNAL OF CANCER (2023)

Article Multidisciplinary Sciences

Multi-center matched cohort study of convalescent plasma for hospitalized patients with COVID-19

Cindy Ke Zhou, Monica M. Bennett, Carlos H. Villa, Kendall P. Hammonds, Yun Lu, Jason Ettlinger, Elisa L. Priest, Robert L. Gottlieb, Steven Davis, Edward Mays, Tainya C. Clarke, Azadeh Shoaibi, Hui-Lee Wong, Steven A. Anderson, Ronan J. Kelly

Summary: This study investigated the effectiveness and safety of COVID-19 convalescent plasma (CCP) in hospitalized COVID-19 patients in a multi-hospital healthcare system in Texas. The study found no significant difference in 28-day in-hospital all-cause mortality between the treatment and control groups, but CCP-treated patients were less likely to be discharged alive and more likely to receive mechanical ventilation. Safety outcomes were similar between the two groups.

PLOS ONE (2022)

Article Multidisciplinary Sciences

Assessment of performance characteristics of COVID-19 ICD-10-CM diagnosis code U07.1 using SARS-CoV-2 nucleic acid amplification test results

Keran Moll, Shayan Hobbi, Cindy Ke Zhou, Kathryn Fingar, Timothy Burrell, Veronica Hernandez-Medina, Joyce Obidi, Nader Alawar, Steven A. Anderson, Hui-Lee Wong, Azadeh Shoaibi

Summary: This study evaluated the performance of ICD-10-CM diagnosis code U07.1 in identifying COVID-19 cases in claims databases and found that it performed well. The results indicate that the performance of U07.1 may vary across populations and time periods.

PLOS ONE (2022)

Article Immunology

Near real-time surveillance of safety outcomes in US COVID-19 vaccine recipients aged 12 to 64 years

Patricia C. Lloyd, Mao Hu, Hui-Lee Wong, Azadeh Shoaibi, Cindy Ke Zhou, An-Chi Lo, Kandace Amend, Daniel C. Beachler, Cheryl N. McMahill-Walraven, Elizabeth R. Smith, John Seeger, Alex Secora, Djeneba Audrey Djibo, Joyce Obidi, Yuhui Feng, Jennifer Song, Christian Reich, Charalynn Harris, Sandia Akhtar, Robin Clifford, Nandini Selvam, Jennifer L. Pigoga, Yixin Jiao, Yoganand Chillarige, Thomas MaCurdy, Richard Forshee, Steven A. Anderson

Summary: This study utilized an early warning rapid surveillance system in three large commercial insurance databases to monitor safety outcomes following COVID-19 vaccination. The results identified signals for myocarditis/pericarditis and anaphylaxis as adverse outcomes of the vaccination. The findings provide valuable information for early detection of potential safety concerns.

VACCINE (2022)

Article Immunology

Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020

Keran Moll, Bradley Lufkin, Kathryn R. Fingar, Cindy Ke Zhou, Ellen Tworkoski, Chianti Shi, Shayan Hobbi, Mao Hu, Minya Sheng, Jillian McCarty, Shanlai Shangguan, Timothy Burrell, Yoganand Chillarige, Jeff Beers, Patrick Saunders-Hastings, Stella Muthuri, Kathryn Edwards, Steven Black, Jeff Kelman, Christian Reich, Kandace L. Amend, Djeneba Audrey Djibo, Daniel Beachler, Rachel P. Ogilvie, Alex Secora, Cheryl N. McMahill-Walraven, John D. Seeger, Patricia Lloyd, Deborah Thompson, Rositsa Dimova, Thomas MaCurdy, Joyce Obidi, Steve Anderson, Richard Forshee, Hui-Lee Wong, Azadeh Shoaibi

Summary: The FDA conducts active surveillance of adverse events following COVID-19 vaccination for the BEST Initiative. The study found that the incidence rates of most adverse events increased with age, but Medicare enrollees had lower rates compared to commercially insured adults. From March to May 2020, the incidence rates of most adverse events decreased compared to the same period in 2019, but returned to pre-pandemic levels afterwards.

VACCINE (2023)

Article Immunology

Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older

Hui-Lee Wong, Ellen Tworkoski, Cindy Ke Zhou, Mao Hu, Deborah Thompson, Bradley Lufkin, Rose Do, Laurie Feinberg, Yoganand Chillarige, Rositsa Dimova, Patricia C. Lloyd, Thomas MaCurdy, Richard A. Forshee, Jeffrey A. Kelman, Azadeh Shoaibi, Steven A. Anderson

Summary: This study evaluated the outcomes following COVID-19 vaccination in elderly persons and found a slight increase in the risk of pulmonary embolism, acute myocardial infarction, disseminated intravascular coagulation, and immune thrombocytopenia after receiving the BNT162b2 vaccine. However, after further evaluation, only the risk of pulmonary embolism still met the statistical threshold, while the risks of the other outcomes did not. More research is needed to determine the causal relationship between the vaccines and these outcomes.

VACCINE (2023)

Article Public, Environmental & Occupational Health

Use of Structured Electronic Health Records Data Elements for the Development of Computable Phenotypes to Identify Potential Adverse Events Associated with Intravenous Immunoglobulin Infusion

Jillian H. H. Hurst, Amanda Brucker, Congwen Zhao, Hannah Driscoll, Haley P. P. Hostetler, Michael Phillips, Bari Rosenberg, Marc D. D. Samsky, Isaac Smith, Megan E. E. Reller, John J. J. Strouse, Cindy Ke Zhou, Graca M. Dores, Hui-Lee Wong, Benjamin A. A. Goldstein

Summary: Detecting adverse reactions to drugs and biologic agents is important for regulatory approval and post-market safety evaluation. Real-world data, including insurance claims and electronic health records data, are increasingly being used for evaluating potential safety outcomes. However, different types of data elements within these resources can affect the development and performance of computable phenotypes for identifying adverse events (AEs).

DRUG SAFETY (2023)

Article Hematology

Immune globulin usage trends in commercially insured and Medicare populations, 2009-2019

Yixin Jiao, Keran Moll, Graca M. Dores, Ellen Tworkoski, Cindy Ke Zhou, Dorothy Scott, Hui-Lee Wong, Kathryn Fingar, Timothy Burrell, Rowan McEvoy, Shayan Hobbi, Yoganand Chillarige, Joyce Obidi, Thomas MaCurdy, Jeffrey Kelman, Azadeh Shoaibi

Summary: This study describes the utilization patterns of immune globulins (IG) in the United States from 2009 to 2019, showing an overall increase in IG administrations, recipients, and doses. The main driver of this trend is the population of immunodeficient individuals.

TRANSFUSION (2023)

Article Immunology

Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: Two self-controlled studies in the US

Azadeh Shoaibi, Patricia C. Lloyd, Hui-Lee Wong, Tainya C. Clarke, Yoganand Chillarige, Rose Do, Mao Hu, Yixin Jiao, Andrew Kwist, Arnstein Lindaas, Kathryn Matuska, Rowan McEvoy, Michelle Ondari, Shruti Parulekar, Xiangyu Shi, Jing Wang, Yun Lu, Joyce Obidi, Cindy K. Zhou, Jeffrey A. Kelman, Richard A. Forshee, Steven A. Anderson

Summary: A self-controlled case series study of COVID-19 mRNA vaccines in U.S. Medicare beneficiaries aged > 65 years showed a slight increase in the risk of acute myocardial infarction and pulmonary embolism following vaccination. However, there was no evidence to support an increased risk of immune thrombocytopenia, disseminated intravascular coagulation, Bell's Palsy, and myocarditis/pericarditis associated with COVID-19 mRNA vaccines.

VACCINE (2023)

Article Microbiology

Characterization of COVID-19 Hospitalized Patients in Three United States Electronic Health Record Databases

Patrick Saunders-Hastings, Cindy Ke Zhou, Shayan Hobbi, Eva Boyd, Patricia Lloyd, Nader Alawar, Timothy Burrell, Jeff Beers, Tainya C. C. Clarke, Aaron Z. Z. Hettinger, Hui-Lee Wong, Azadeh Shoaibi

Summary: This study provides an overview of the demographics, clinical characteristics, treatments, and outcomes of hospitalized COVID-19 patients in the U.S. during the pre-vaccine phase. The majority of patients were over 30 years old and had comorbidities such as cardiovascular/respiratory diseases and diabetes. Anticoagulants were commonly used, and the administration of remdesivir increased over time. Patients showed higher disease severity after 14 days of admission compared to before admission. The median length of hospital stay was 4-6 days, and most patients were discharged alive.

PATHOGENS (2023)

Article Medicine, General & Internal

Use of Immunization Information Systems in Ascertainment of COVID-19 Vaccinations for Claims-Based Vaccine Safety and Effectiveness Studies

Karen L. Schneider, Elizabeth J. Bell, C. K. Zhou, Grace Yang, Patricia Lloyd, Tainya C. Clarke, Michael Wilkinson, Emily E. Myers, Kandace L. Amend, John D. Seeger, Yoganand Chillarige, Richard A. Forshee, Azadeh Shoaibi, Steven A. Anderson, Hui-Lee Wong

Summary: This study evaluated the association between Immunization Information Systems (IIS) data and healthcare claims data to improve the accuracy of COVID-19 vaccine coverage estimation. The findings showed that supplementing claims data with IIS vaccination records substantially increased the number of individuals identified as vaccinated, but potential underrecording remained. Improvement in reporting vaccination data to IIS infrastructures could allow frequent updates of vaccination status for all individuals and all vaccines.

JAMA NETWORK OPEN (2023)

Article Medicine, General & Internal

Development and Validation of an Algorithm for Thrombosis with Thrombocytopenia Syndrome (TTS) at Unusual Sites

Shayan Hobbi, Patrick Saunders-Hastings, Cindy Ke Zhou, Jeffrey Beers, Ananth Srikrishnan, Aaron Hettinger, Aarthi Shenoy, Timothy Burrell, Keran Moll, Patricia C. Lloyd, Steven A. Anderson, Azadeh Shoaibi, Hui-Lee Wong

Summary: This study validates the accuracy of an ICD-10-CM-based algorithm for unusual site TTS, demonstrating a high positive predictive value for diagnosing unusual site TTS. The algorithm can be used in observational studies to actively monitor the safety and effectiveness of COVID-19 vaccines and other medical products.

INTERNATIONAL JOURNAL OF GENERAL MEDICINE (2023)

Correction Oncology

Recommended Definitions of Aggressive Prostate Cancer for Etiologic Epidemiologic Research (vol 113, pg 727, 2021)

Lauren M. Hurwitz, Ilir Agalliu, Demetrius Albanes, Kathryn Hughes Barry, Sonja I. Berndt, Qiuyin Cai, Chu Chen, Iona Cheng, Jeanine M. Genkinger, Graham G. Giles, Jiaqi Huang, Corinne E. Joshu, Tim J. Key, Synnove Knutsen, Stella Koutros, HilDe langseth, Sherly X. Li, Robert J. MacInnis, Sarah C. Markt, Kathryn L. Penney, Aurora Perez-Cornago, Thomas E. Rohan, Stephanie A. Smith-Warner, Meir J. Stampfer, Konrad H. Stopsack, Catherine M. Tangen, Ruth C. Travis, Stephanie J. Weinstein, Lang Wu, Eric J. Jacobs, Lorelei A. Mucci, Elizabeth A. Platz, Michael B. Cook

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)

暂无数据